Document Detail

The effect of long-term treatment with sulindac on the progression of diabetic retinopathy.
MedLine Citation:
PMID:  17621415     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To evaluate the effects of long-term treatment with sulindac on the progression of diabetic retinopathy (DR). RESEARCH DESIGN AND METHODS: 40 Japanese patients with type 2 diabetes were enrolled in a randomized, single-blind controlled trial in which the effects of sulindac (200 mg/day, 100 mg twice a day; n = 16 patients) on the progression of DR were compared to controls (24 patients) for 3 years. All patients were comparable in their age, gender, duration of disease, body mass index, dipstick proteinuria, insulin therapy, glycemic control, and clinical stages of DR. Outcome was determined by comparing parameters of retinopathy in fundus photographs that were taken at time 0 to those taken 1, 2, and 3 years after the initiation of treatment. RESULTS: Patients in the sulindac group did not develop DR during the course of treatment nor was there progression of pathology in those who began the study with mild non-proliferative DR (NPDR). On the other hand, six patients progressed to mild NPDR in the control group--three at year 1 and three at year 3--and an additional patient progressed to severe NPDR from mild NPDR by year 1 and to proliferative DR by year 2. The findings at year 3 in the sulindac group were significantly (p < 0.05) different from the control group. None of the patients experienced any adverse effects of treatment. CONCLUSIONS: Long-term treatment with sulindac was clinically effective in decreasing the progression of mild DR in type 2 diabetic patients in this pilot study.
Yukiko Hattori; Kiyoshi Hashizume; Kazuo Nakajima; Yoshihiro Nishimura; Motoji Naka; Kazuto Miyanaga
Related Documents :
18194595 - Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with ...
11137095 - Effects of initial and long-term lipid-lowering therapy on vascular wall characteristics.
9816555 - Attitude changes of general practitioners towards lowering ldl cholesterol.
19837545 - Aggressive lipid-lowering is more effective than moderate lipid-lowering treatment in c...
11008725 - A randomized trial of glyceryl trinitrate ointment and nitroglycerin patch in healing o...
10456395 - European system for cardiac operative risk evaluation (euroscore).
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Current medical research and opinion     Volume:  23     ISSN:  1473-4877     ISO Abbreviation:  Curr Med Res Opin     Publication Date:  2007 Aug 
Date Detail:
Created Date:  2007-08-16     Completed Date:  2007-10-17     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0351014     Medline TA:  Curr Med Res Opin     Country:  England    
Other Details:
Languages:  eng     Pagination:  1913-7     Citation Subset:  IM    
Department of Internal Medicine, Asama General Hospital, Saku, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cyclooxygenase Inhibitors / therapeutic use*
Diabetic Retinopathy / drug therapy*
Disease Progression
Middle Aged
Single-Blind Method
Sulindac / therapeutic use*
Reg. No./Substance:
0/Cyclooxygenase Inhibitors; 38194-50-2/Sulindac

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Are alexithymia and emotional characteristics of disclosure associated with blood pressure reactivit...
Next Document:  Sherlock Holmes: an expert's view of expertise.